2023
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer
Tan W, McElree I, Davaro F, Steinberg R, Bree K, Navai N, Dinney C, O'Donnell M, Li R, Kamat A, Packiam V. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer. European Urology Oncology 2023, 6: 531-534. PMID: 37468392, DOI: 10.1016/j.euo.2023.06.011.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerBacillus Calmette-GuerinIntermediate-risk non-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder cancerIntermediate-riskMulti-institutional retrospective reviewBlue light cystoscopyCombination of docetaxelEvaluate oncological outcomesHigh-grade diseaseMedian follow-upCancer-specific mortalityTreatment groupsCancer control outcomesBladder cancer groupSequential gemcitabineChemotherapy combinationsOncological outcomesIntravesical gemcitabinePostoperative chemotherapyAdjuvant treatmentRetrospective reviewRecurrence rateCancer group
2021
Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
Zhao H, Chan V, Castellani D, Chan E, Ong W, Peng Q, Moschini M, Krajewski W, Pradere B, Ng C, Enikeev D, Vasdev N, Ekin G, Sousa A, Leon J, Guerrero-Ramos F, Tan W, Kelly J, Shariat S, Witjes J, Teoh J. Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Frontiers In Surgery 2021, 8: 775527. PMID: 34888347, PMCID: PMC8649716, DOI: 10.3389/fsurg.2021.775527.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerHigh-risk non-muscle invasive bladder cancerInvasive bladder cancerOncological outcomesSafety profileBladder cancerAdverse eventsMeta-analysisBacillus Calmette-Guerin instillationsHigh-risk NMIBC patientsIntravesical bacillus Calmette-GuerinMeta-analysis of clinical studiesBCG maintenance therapySystematic reviewMonths recurrence rateCochrane RoB toolCertainty of evidenceRisk of biasComprehensive literature searchBCG shortageChemotherapy maintenanceNMIBC patientsBCG treatmentMaintenance therapyRecurrence rate1459 Intravesical Chemohyperthermia Versus Bacillus Calmette-Guerin Instillation for Intermediate- And High-Risk Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
Zhao H, Chan V, Castellani D, Chan E, Ong W, Peng Q, Moschini M, Krajewski W, Pradere B, Ng C, Enikeev D, Vasdev N, Ekin G, Sousa A, Leon J, Guerrero-Ramos F, Tan W, Kelly J, Shariat S, Witjes J, Teoh J. 1459 Intravesical Chemohyperthermia Versus Bacillus Calmette-Guerin Instillation for Intermediate- And High-Risk Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. British Journal Of Surgery 2021, 108: znab259.955. DOI: 10.1093/bjs/znab259.955.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerHigh-risk non-muscle invasive bladder cancerRecurrence-free survivalProgression-free survivalInvasive bladder cancerCarcinoma in situChemo-hyperthermiaAdverse eventsChemotherapy instillationSafety profileBladder cancerBCG groupBCG maintenance therapyTrans-urethral resectionMeta-analysisMonths recurrence rateSystematic reviewComprehensive literature searchQuality of evidenceBCG failureBCG shortageMaintenance therapyOncological outcomesRandomised controlled trialsRecurrence rate